ajaz Hussain

2 months ago | outsourcedpharma.com | Louis Garguilo |ajaz Hussain

CDMOs seem determined to do two things more strategically and with a greater focus: build on what they do best (instead of spreading across services); and differentiate themselves by a devotion to customer service. Part two from JPM25. Deploy AI To Become A cGMP 'Special Agent' With A License To CareAddressing systemic cGMP issues requires more than technical fixes — it demands organizational transformation.

2 months ago | pharmaceuticalonline.com | ajaz Hussain |Jason Boyd |Abhijeet S. Sinha

Webinar: De-Risking Early Phase Micronization with Integrated Solid Form SelectionJet milling is a well-established technology used to micronize APIs for respiratory delivery. Careful selection of the API solid form, whether salt, cocrystal or solvate, is crucial for successful micronization if the desired particle size is to be achieved in a high yield. Learn how to identify viable salt/cocrystal forms for micronization feasibility and enhancing solubility. Click here to learn more.

Jan 16, 2025 | biosimilardevelopment.com | ajaz Hussain |Yadnyesh Patel |Vaibhav Patel

With a third wave of biologics patents expiring, the race is on to seize the booming opportunities in the fast-evolving biosimilars field. What’s driving the patent scramble? What hurdles in manufacturing, regulation, and market access must be cleared for biosimilars to thrive? And how are global industry leaders carving out strategies to dominate the market? Don’t miss Bioprocess Online Live happening February 4th.

Jan 14, 2025 | pharmaceuticalonline.com | ajaz Hussain |Robert Kegan

By Ajaz S. Hussain, Ph.D., independent subject matter expert Over the past decades, efforts to foster holistic healthcare and good pharmaceutical practices have centered on integrating design thinking and system-based approaches. However, their implementation during the COVID-19 pandemic revealed significant gaps, failing to deliver a unified public health response.

Jan 7, 2025 | pharmaceuticalonline.com | ajaz Hussain

By Ajaz S. Hussain, Ph.D., independent subject matter expert The pharmaceutical industry struggles with current good manufacturing practices (cGMP) violations and other systemic issues. cGMPs are foundational standards ensuring drug quality and safety. Deficiencies in quality systems, inadequate training, and recurring cGMP failures compromise public health, disrupt supply chains, and undermine industry credibility.